Cash burn is the clock every pipeline runs against

A promising pipeline is worth something only if the company can fund it to the finish line. The rate at which it burns cash decides how long the science has to work, and whether shareholders get diluted before it does.

Runway against milestones

Late-stage trials are expensive, and revenue from new products arrives years after the spending. A company whose legacy revenue is shrinking has to cross that gap on its balance sheet. If the runway is shorter than the time to meaningful new revenue, the difference is filled by cost cuts, partnerships or new shares.

None of that means the pipeline is weak. It means the pipeline is being valued on a timeline the cash may not support.

What I'm watching

• Cash and investments against annual burn
• Milestones that could bring partner funding
• Cost reduction targets, and whether they touch research

Where I stand

Short, on a runway that looks tight against the time new products need. The science can be right and the shares can still suffer on the way.

What would change my mind

A partnership that funds late-stage work, or a launch that ramps faster than planned. Either would extend the clock, which is the variable that matters most here.